Summit Therapeutics, Inc.

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: US86627T1088

USD

14.25

-0.03 (-0.21%)

Jun 23

NAS

View all stocks in this country

Company CV

About Summit Therapeutics, Inc.

stock-summary

Summit Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Summit Therapeutics Inc. is focused on developing treatments for infectious diseases. The Company uses its Discuva platform, an antibiotic discovery engine to develop antibiotics. It is initially focused on Clostridioides difficile infections (CDI). Its platform is designed to uncover novel bacterial targets and develops new mechanism antibiotics against them. Ridinilazole is its new mechanism antibiotic, which is being developed for CDI.

Company Coordinates

Company Details

One Broadway, 14Th Floor , CAMBRIDGE MA : 02142

stock-summary

Tel: 1 617 5147149

stock-summary

stock-summary

Registrar Details

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Domestic Funds

Held in 51 Schemes (6.68%)

Foreign Institutions

Held by 137 Foreign Institutions (2.56%)

Strategic Entities with highest holding

Highest Public shareholder

Board of Directors

Management

Designation

Dr. Elaine Stracker

Executive Director

Mr. Rainer Erdtmann

Non-Executive Independent Director

Stock DNA

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-189 Million

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 12,856 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

NA

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-163.86%

Price to Book

19.51